市場調查報告書
商品編碼
1273578
到 2028 年切向流過濾市場預測 - 按產品、膜材料(尼龍、聚偏二氟乙烯等)、技術、應用、最終用戶和地區分列的全球分析Tangential Flow Filtration Market Forecasts to 2028 - Global Analysis By Product, Membrane Material (Nylon and Polyvinylidene Difluoride and Other Materials), Technique, Application, End User and By Geography |
根據Stratistics MRC,2022年全球切向流過濾市場規模將達到15億美元,預計2028年將達到35億美元,預測期內增長15.2%。以復合年增長率增長
切向流過濾 (TFF) 是純化和分離生物分子的有效方法。 切向流過濾,也稱為錯流過濾,可用於細胞收穫的上游過程和生物製造中使用的下游過程。 從 10 mL 到數千升的樣品溶液都可以濃縮和脫鹽。 通過大量分離收穫的細胞懸浮液、小生物分子、發酵液、細胞裂解物等獲得。
根據塔夫茨藥物開發研究中心 2021 年的一份報告,最大的上市生物技術公司的全球研發支出增長了 13.7%每年從 2001 年的 48 億美元增加到 2020 年的 550 億美元
典型的切向流過濾工藝包括反滲透和納濾。 濃縮和滲濾技術使用切向流過濾。 它通過去除液體同時保留溶質分子來增加溶液的濃度。 在滲濾中,小顆粒與大顆粒分離,剩餘的鹽分用另一種緩衝液洗掉,最後留下小顆粒,總濃度不變。 該方法也可用於通過用水洗去殘留的鹽來降低溶液的濃度。 因此,切向流過濾利用率的提高正在推動預測期內切向流過濾市場的增長。
建造或新建製造設備需要大量的資金投入,小企業可能難以有備選方案應對。 此外,離心、直流過濾和預塗過濾等尖端技術的出現預計將阻礙全球切向流過濾市場的擴張。 此外,許多製藥公司不斷將生產外包,以有效利用海外的技術、經驗和能力。 結果,成品價格將上漲,這可能會阻礙市場擴張。
切向流過濾 (TFF) 是一種快速有效的生物分子分離和純化技術。 它在許多科學領域都很有用,例如免疫學、蛋白質化學、分子生物學(DNA/RNA/寡核甘酸)、生物化學和微生物學。 多年來,TFF 一直用於濃縮和脫鹽蛋白質和□,從細胞培養基中回收和純化抗體和重組蛋白質,以及分離稀釋的蛋白質混合物。 此外,隨著治療方式轉向重症監護,轉基因蛋白質的治療應用正在擴大。 生物製藥行業正趨向於將重組蛋白商業化,這預計將推動切向流過濾市場的增長。
預計在預測期內,製藥行業普遍存在嚴格的政府法規,這將為全球切向流過濾市場帶來挑戰。 此外,市場上既定且強大的競爭對手的存在使新進入者難以為其產品和新技術做廣告。 此外,該市場的主要競爭對手提供範圍廣泛的過濾產品,並享有較高的客戶品牌忠誠度,這使得新進入者更難在該行業立足。
COVID-19 大流行增加了全球經濟和社會成本,促使各國政府加緊疫苗開發和製造。 切向流過濾產品越來越多地用於 COVID-19 研究。 各種過濾技術和材料用於支持下游過程,例如用於疫苗開發的過濾和純化。 此外,一些生物製藥公司已採取多種策略來改進疫苗開發並遏制大流行。 COVID-19 疫情也為過濾器製造商擴大生產設施創造了機會。 這些過濾產品用於製造疫苗和其他醫藥產品,因此疫苗的大規模生產對切向流過濾產品的需求產生了積極影響。
由於過濾系統在許多行業(尤其是製藥行業)中的使用,據估計膜過濾器將獲得有利可圖的增長。 這一領域的擴大是由於容易獲得各種類型的過濾器,如 PCTE、PVDF、PTFE 和 PES。 此外,相關工藝中各種膜過濾面積和孔徑的可用性也在推動該領域的擴展。
由於在細胞分離過程中越來越多地使用微濾技術,預計微濾部分在預測期內將以最快的複合年增長率增長。 另一方面,微濾膜用於應對微生物去除、蛋白質分離和膜處理等各種挑戰,推動了該細分市場的擴張。 此外,由於孔徑在0.1到10m之間變化,因此可以抑制結垢和分離懸浮顆粒。 這些因素預計將在預測期內促進該部門的增長。
亞太地區受到生物製劑和製藥需求不斷增長、國內外公司大量投資以及 CMO 在中國、日本和韓國等新興市場擴張的推動,推動了該行業的增長。 , 預計在預測期內將佔據最大的市場份額。 此外,治療的現代化、醫療保健基礎設施的發展以及對低成本藥品需求的關注預計將推動亞太地區 TFF 市場的增長。
預計北美在預測期內的複合年增長率最高。 這是由於為滿足生物治療需求而增加的生物工藝活動、慢性病和遺傳異常的頻率增加、治療安全知識的增加以及醫療保健環境的改善正在支持該地區的增長。 此外,政府的支持也促進了發展。
2021 年 12 月,唐納森公司(美國)將收購 Solaris S.p.A.(意大利),該公司設計和製造生物工藝設備,例如用於生物技術和其他生命科學市場的切向流過濾系統。 此次收購擴大了公司在製藥行業的投資組合。
2020 年 3 月,丹納赫從通用電氣公司手中收購了生物製藥業務。 該部門將被稱為 Cytiva,並將成為丹納赫生命科學部門下運營的一家獨立公司。
According to Stratistics MRC, the Global Tangential Flow Filtration Market is accounted for $1.5 billion in 2022 and is expected to reach $3.5 billion by 2028 growing at a CAGR of 15.2% during the forecast period. Tangential flow filtration (TFF) is an effective approach for biomolecule purification and separation. Tangential flow filtration, also known as cross-flow filtration, is useful in both the upstream processing of cell harvesting and the downstream processing approach utilised in bio-manufacturing. It concentrates and desalts sample solutions in amounts ranging from 10 mL to thousands of litres. It is obtained through massive fractionation of harvest cell suspensions, tiny biomolecules, fermentation broths, and cell lysates.
According to a US-based independent, academic, non-profit research center, Tufts Center for the Study of Drug Development's 2021 report, the global R&D spending by the largest publicly-traded biotech companies grew 13.7% annually, from $4.8 billion in 2001 to $55.0 billion in 2020
Typical tangential flow filtering processes include reverse osmosis and nanofiltration. In concentration and diafiltration techniques, tangential flow filtration is used. It increases a solution's concentration by removing liquids while maintaining the solute molecules. In diafiltration, tiny and giant particles separate, leaving the tinier particles behind without changing the total concentration at the end by washing out the rest of the salt with another buffer. This approach can also be used to reduce the concentration of a solution by washing away the remaining salts with water. Tangential flow filtration's increasing use is thus fuelling the growth of the Tangential Flow Filtration Market during the forecast period.
High capital expenditure is necessary to construct and establish new manufacturing facilities, which may be difficult or easy to option out by small-scale businesses. Furthermore, the presence of cutting-edge technologies such as centrifugation, direct flow filtration, and pre-coat filtration is expected to hamper the worldwide tangential flow filtration market's expansion. Furthermore, numerous pharmaceutical corporations are constantly outsourcing manufacturing in order to effectively utilise foreign technology, experience, and capacity. As a result, the prices of finished items may rise, stifling market expansion.
Tangential flow filtration (TFF) is an immediate and effective technique for biomolecule separation and purification. It is useful in many scientific domains, including immunology, protein chemistry, molecular biology (DNA/RNA/oligonucleotides), biochemistry, and microbiology. TFF has been used to concentrate and desalt proteins and peptides, recover and purify antibodies or recombinant proteins from cell culture medium, and fractionate dilute protein mixtures over the years. Recombinant proteins have received substantial momentum for therapeutic uses as the treatment pattern has shifted towards focused therapy. The biopharmaceutical industry's tendency of commercialising recombinant proteins is projected to drive the growth of the tangential flow filtration market.
The prevalence of rigorous government laws and regulations in the pharmaceutical business is expected to offer a challenge to the worldwide tangential flow filtration market during the forecast period. Furthermore, the market's presence of well-established and prominent competitors makes it difficult for new entrants to advertise their product offers and novel technology. Furthermore, important competitors in this market offer a wide selection of filtration products and have high levels of brand loyalty from customers, making it even more difficult for new entrants to establish a foothold in the industry.
The COVID-19 pandemic increased the global economic and social cost, prompting governments to increase vaccine development and manufacturing. Tangential flow filtration products are increasingly being used for COVID-19 research. To support downstream processes such as filtration and purification for vaccine development, various filtration techniques and materials are used. Moreover, some biopharmaceutical companies have incorporated several strategies to improve vaccine development and contain the pandemic. The COVID-19 epidemic has also created chances for filter manufacturers to expand their manufacturing facilities. As these filtering goods are utilised in the production of vaccines and other medicinal medications, the mass production of vaccines has favourably influenced the demand for tangential flow filtration products.
The membrane filters segment is estimated to have a lucrative growth, due to the use of filtering systems in numerous industries, particularly the pharmaceutical industry, is the primary driver of this segment's growth. The segment's expansion is being driven by the ease of access to various types of filters such as PCTE, PVDF, PTFE, and PES. Furthermore, the availability of diverse membrane filtration areas and pore sizes for relevant processes encourages segment expansion.
The microfiltration segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the increased use of microfiltration techniques during cell separation procedures. Microfiltration membranes, on the other hand, are used to handle a variety of challenges such as microbial removal, protein separation, and membrane treatment, which is driving the segment's expansion. Furthermore, these membranes are available in a variety of pore diameters ranging from 0.1 to 10 m, which aids in limiting fouling and fractionating suspended particles. These factors will contribute to the segment's growth during the predicted period.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the growing demand for biologics and medicines, considerable investments from domestic and international firms, and the expansion of CMOs in emerging markets such as China, Japan, and South Korea are all driving to the industry's growth. Furthermore, the focus on treatment modernization, healthcare infrastructure development, and need for low-cost pharmaceuticals would drive the growth of the TFF market in APAC.
North America is projected to have the highest CAGR over the forecast period, owing to the increased bioprocessing activities to meet bio-therapeutic demand, increased frequency of chronic diseases and genetic abnormalities, expanding knowledge about treatment safety, and enhanced healthcare settings have all supported regional growth. Furthermore, the presence of a supportive government promotes development.
Some of the key players profiled in the Tangential Flow Filtration Market include: Andritz, Synder Filtration, INC., Merk KGAA, SPF Technologies, LLC, Parker Hannifin Corporation, Danaher Corporation, Sysbiotech Gmbh, Solaris Biotechnology SRL, Alfa Laval Corporate AB, Sartorius AG, Sterlitech Corporation, Koch Separation Solutions, Cole-Parmer Instrument Company, LLC, Repligen Corporation and Meissner Filtration Products, INC.
In December 2021, Donaldson Company (US) acquired Solaris (Italy), a company that designs and manufactures bioprocessing equipment, including tangential flow filtration systems for use in biotechnology, and other life sciences markets. This acquisition will expand the company's portfolio in the pharmaceutical industry.
In March 2020, Danaher acquired the biopharma business from General Electric Company. This division will be called Cytiva and will be a standalone company operating under the Danaher Life Sciences segment.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.